B' Department of Neurology, Laboratory of Experimental Neurology and Neuroimmunology, AHEPA University Hospital, Stilponos Kiriakides str. 1, 54636, Thessaloniki, Macedonia, Greece.
Mol Neurobiol. 2018 Aug;55(8):6329-6336. doi: 10.1007/s12035-017-0841-7. Epub 2018 Jan 2.
Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), have been on the forefront of drug discovery for most of the myelin inhibitory molecules implicated in axonal regenerative process. Nogo-A along with its putative receptor NgR and co-receptor LINGO-1 has paved the way for the production of pharmaceutical agents such as monoclonal antibodies, which are already put into handful of clinical trials. On the other side, little progress has been made towards clarifying the role of neurotrophin receptor p75 (p75NTR) and TROY in disease progression, other key players of the Nogo receptor complex. Previous work of our lab has shown that their exact location and type of expression is harmonized in a phase-dependent manner. Here, in this review, we outline their façade in normal and diseased central nervous system (CNS) and suggest a role for p75NTR in chronic axonal regeneration whereas TROY in acute inflammation of EAE intercourse.
多发性硬化症(MS)及其动物模型,实验性自身免疫性脑脊髓炎(EAE),一直处于大多数涉及轴突再生过程的髓鞘抑制分子的药物发现的前沿。Nogo-A 及其假定的受体 NgR 和共受体 LINGO-1 为单克隆抗体等药物的生产铺平了道路,这些药物已经进入了少数临床试验。另一方面,对于神经营养素受体 p75(p75NTR)和 TROY 在疾病进展中的作用,即 Nogo 受体复合物的其他关键成员,几乎没有取得任何进展。我们实验室之前的工作表明,它们的确切位置和表达类型以依赖于阶段的方式协调一致。在这里,在这篇综述中,我们概述了它们在正常和患病中枢神经系统(CNS)中的表现,并提出了 p75NTR 在慢性轴突再生中的作用,而 TROY 在 EAE 炎症的急性期中的作用。